Harley-Davidson is synonymous with power, heritage, and the spirit of freedom on two wheels. With over a century of legendary ...

The touring motorcycle segment, in general, represents a relatively small number of models when compared to the total number ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Eli Lil­ly is buy­ing Organo­vo’s far­ne­soid X re­cep­tor (FXR) ag­o­nist pro­gram, which in­cludes a drug in Phase 2 de­vel­op­ment for ul­cer­a­tive col­i­tis and meta­bol ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in 3D human tissue models, has reached an agreement to sell its FXR program, including the lead asset FXR314 ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

The buzz early was what was in John Garrett’s bass bag. It was Dollar Bill Lowen that created the biggest buzz as he weighed in 18 pounds, 1 ounce to maintain his lead at the 2025 FXR P ...